{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:38:37Z","timestamp":1794605917053,"version":"4.9.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy is still the standard treatment for stage III-N2 nonsmall cell lung cancer after R0 resection, and it is still controversial whether conventional adjuvant radiotherapy is needed. We used meta-analysis to try to answer whether adjuvant postoperative chemoradiotherapy (POCRT) can bring survival benefits to patients with stage III-N2 nonsmall cell lung cancer after R0 resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Up to June 25, 2021, the databases of PubMed, Embase, Cochrane Library, CNKI, and Wanfang were searched, and clinical studies on POCRT for stage III-N2 nonsmall cell lung cancer were included. RevMan5.4 software was used for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 8959 patients were included in 5 randomized controlled trials and 17 retrospective studies. The results of the meta-analysis showed that POCRT could improve 3 and 5 years overall survival (OS) rate (OR = 1.52, 95%CI: 1.05\u20132.20; OR = 1.30, 95%CI: 1.16\u20131.46), 3 and 5 years disease-free survival (DFS) rate (OR = 1.34, 95%CI: 1.01\u20131.76; OR = 1.74, 95%CI: 1.43\u20132.12), and 5-year locoregional recurrence-free survival (LRFS) rate (OR = 2.69, 95%CI: 1.76\u20134.11) in patients with stage III-N2 nonsmall cell lung cancer compared with adjuvant postoperative chemotherapy (POCT) alone. But could not improve 5-year distant metastasis-free survival (DMFS) rate (OR = 1.14, 95%CI: 0.52\u20132.52). The results of subgroup analysis showed that postoperative sequential chemoradiotherapy could improve the 3 and 5 years OS rate (OR = 2.06, 95%CI: 1.22\u20133.46; OR = 1.39, 95%CI: 1.21\u20131.59). Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) can improve the 3 and 5 years OS rate (OR = 1.80, 95%CI: 1.09\u20132.99; OR = 1.31, 95%CI: 1.04\u20131.66). In addition, POCRT could improve the 3-year OS rate (OR = 1.88, 95%CI: 1.21\u20132.92) in patients with N2 single-station lymph node metastasis compared with POCT alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared with POCT alone, adjuvant POCRT can significantly improve the overall survival rate of patients with NSCLC after R0 resection of stage III-N2, especially in patients with N2 single-station lymph node metastasis. Accurate radiotherapy techniques such as 3DCRT or IMRT are recommended, and postoperative sequential chemoradiotherapy is the best treatment mode.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000029580","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:08:54Z","timestamp":1662635334000},"page":"e29580","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0644-4791","authenticated-orcid":false,"given":"Dailong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People\u2019s Hospital, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(13)61502-0","article-title":"Management of non-small-cell lung cancer: recent developments","volume":"382","author":"Reck","year":"2013","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1148\/rg.2018170081","article-title":"Revisions to the TNM staging of lung cancer: rationale, significance, and clinical application","volume":"38","author":"Carter","year":"2018","journal-title":"Radiographics"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.21037\/tlcr-20-1210","article-title":"Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists","volume":"10","author":"Glatzer","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00268-017-4165-6","article-title":"The significance of upfront knowledge of N2 disease in non-small cell lung cancer","volume":"42","author":"Thomas","year":"2018","journal-title":"World J Surg"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2000.18.16.2981","article-title":"Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications","volume":"18","author":"Andre","year":"2000","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2009.23.2272","article-title":"Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer","volume":"28","author":"Arriagada","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9722","key":"R7-20250504","doi-asserted-by":"crossref","first-page":":1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1634\/theoncologist.2010-0150","article-title":"Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data","volume":"16","author":"Le P\u00e9choux","year":"2011","journal-title":"Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/PPO.0b013e318074def2","article-title":"Rectal cancer radiotherapy","volume":"13","author":"Ramsey","year":"2007","journal-title":"Cancer J"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2017.11.005","article-title":"Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?","volume":"126","author":"Monten","year":"2018","journal-title":"Radiother Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2020.1760094","article-title":"Current radiotherapy techniques in NSCLC: challenges and potential solutions","volume":"20","author":"Giaj-Levra","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R16-20250504","first-page":"452","article-title":"Analyze the curative effect of adjuvant radiotherapy in stage IIIA(N2) non-small cell lung cancer","volume":"06","author":"Liu","year":"2013","journal-title":"Chin Oncol"},{"key":"R17-20250504","first-page":"357","article-title":"Clinical application of adjuvant treatment after operation in patients with stage IIIa non-small cell lung cancer","volume":"13","author":"Zhang","year":"2010","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R18-20250504","first-page":"4","article-title":"Clinical study on stage IIIA-N2 non-small cell lung cancer after radical operation","volume":"42","author":"Yong-Li","year":"2018","journal-title":"Heilongjiang Med J"},{"key":"R19-20250504","first-page":"385","article-title":"Comparison of the outcome of complete excision followed by three-dimensional conformal radiation therapy and adjuvant chemotherapy versus adjuvant chemotherapy alone in the treatment of patients with stage IIIA-N2 non-small cell lung cancer","volume":"02","author":"Jin-Tong","year":"2009","journal-title":"West Chin Med J"},{"key":"R20-20250504","first-page":"112","article-title":"Evaluation of postoperative radiotherapy after curative resection in IIIA-N2 non-small cell lung cancer with propensity score matching analysis","volume":"02","author":"Han","year":"2017","journal-title":"Cancer Res Prev Treat"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1016\/j.ijrobp.2017.06.1682","article-title":"Preoperative clinical lymph node staging is valuable in selecting patients with pathological IIIA-N2 non\u2013small cell lung cancer benefiting from postoperative radiation therapy","volume":"99","author":"Deng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1326-6","article-title":"The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume","volume":"15","author":"Feng","year":"2015","journal-title":"BMC Cancer"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cllc.2014.05.005","article-title":"Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non\u2013small-cell lung cancer: a propensity score matching analysis","volume":"15","author":"Kim","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3816\/CLC.2007.n.005","article-title":"A phase III study of surgical resection and paclitaxel\/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: cancer and Leukemia Group B 9734","volume":"8","author":"Perry","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2009.05.044","article-title":"A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease","volume":"77","author":"Zou","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2013.10.008","article-title":"Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial","volume":"110","author":"Shen","year":"2014","journal-title":"Radiother Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"718","DOI":"10.6004\/jnccn.2020.7537","article-title":"Effects of postoperative radiotherapy on survival of patients with stage IIIA resected non-small cell lung cancer: analysis of the seer database","volume":"18","author":"Gao","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1186\/s12885-019-6141-z","article-title":"Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis","volume":"19","author":"Su","year":"2019","journal-title":"BMC Cancer"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cam4.2937","article-title":"Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study","volume":"9","author":"Wei","year":"2020","journal-title":"Cancer Med"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1634\/theoncologist.2010-0343","article-title":"Postoperative radiotherapy for resected pathological stage iiia\u2013n2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution","volume":"16","author":"Dai","year":"2011","journal-title":"Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.3747\/co.27.5899","article-title":"Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer","volume":"27","author":"Jin","year":"2020","journal-title":"Curr Oncol"},{"key":"R32-20250504","first-page":"410","article-title":"Effect of adjuvant radiotherapy and chemotherapy on stage IIIA non-small cell lung cancer","volume":"04","author":"Mao","year":"2010","journal-title":"Med Pharm Yunnan"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.01.044","article-title":"Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial","volume":"72","author":"Douillard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with piiia-n2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","journal-title":"JAMA Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jtho.2017.09.1954","article-title":"Randomized phase II trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer","volume":"12","author":"Sun","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtho.2016.09.135","article-title":"Role of postoperative radiotherapy in pathologic stage iiia (n2) non-small cell lung cancer in a prospective nationwide oncology outcomes database","volume":"12","author":"Herskovic","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4143\/crt.2016.442","article-title":"Role of adjuvant thoracic radiation therapy and full dose chemotherapy in pN2 non-small cell lung cancer: elucidation based on single institute experience","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res Treat"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CCO.0000000000000702","article-title":"Adjuvant therapy of operable nonsmall cell lung cancer: an update","volume":"33","author":"Mitsudomi","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"R39-20250504","first-page":"116","article-title":"Factors related to severe acute radiation-induced lung injury caused by IMRT for non-small cell lung cancer.","volume":"03","author":"Yan","year":"2016","journal-title":"Chin J Clin Oncol"},{"key":"R40-20250504","first-page":"921","article-title":"Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer","volume":"9","author":"Lei","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:13:29Z","timestamp":1746317609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":42,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029580","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}